MedDRA stands for Medical Dictionary for Regulatory Activities. It is a standardized medical terminology developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
MedDRA is used internationally to classify adverse event information associated with the use of biopharmaceuticals and other medical products. It provides a consistent way to encode and analyze medical data throughout the regulatory process, from pre-marketing to post-marketing activities.
MedDRA is crucial in clinical research for ensuring consistency and accuracy in reporting adverse events and medical conditions. Its standardized terminology allows researchers and regulatory authorities to efficiently analyze safety data across different studies, pharmaceutical companies, and geographic regions.
The use of MedDRA facilitates clear communication between stakeholders in the drug development process, including sponsors, investigators, and regulatory agencies. It enhances the quality of safety signal detection and evaluation, ultimately contributing to better patient safety and more effective pharmacovigilance practices.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2025 Axcellant